Abstract
Dronedarone is a new, class III antiarrhytmic drug, with electrophysiological proprieties resembling that of amiodarone. However, it has much better safety profile.
Dronedarone is effective bothh for thythm control and heart rate control in patienst with atrial fibrilation. Dronedarone is the first antiarrhytmic drug in which the ability to improve cardiovasular prognosis in atrial fibrilation patients has been demonstrated